

PRESSE RELEASE

Ordinary and Extraordinary General Meeting of 21 May 2010

Villepinte, 25 May 2010

The Ordinary and Extraordinary General Meeting of Guerbet shareholders was held on 21 May 2010 in Villepinte (France) under the chairmanship of Mr. Jean-Jacques Bertrand, Chairman of the Supervisory Board.

All resolutions of the Extraordinary and Ordinary General Meeting were adopted by a large majority.

Shareholders notably voted in favour of the decision to revert to an organization of a French joint stock company (*société anonyme*) governed by a Board of Directors and approved the appointment of the following directors, all former members of the Supervisory Board:

- Mr. Jean-Jacques Bertrand;
- Mr. Philippe Biju-Duval;
- Mr. Jacques Biot;
- Mr. Jacky Boudeville;
- Mr. Olivier Guerbet;
- Mr. Christian Louvet.

The shareholders also approved the appointments of Messrs. Vincent Dagommer and Bernard Massiot to serve on the Board of Directors.

The Board of Directors that met at the close of the Meeting appointed Mr. Jean-Jacques Bertrand as Chairman of the Board.

Mr. Bernard Massiot, previously Chairman of the Executive Board, was appointed Chief Executive Officer (*Directeur Général*) of Guerbet, Ms. Marie-Christine Garnier was appointed Executive Vice President (*Directeur Général Délégué*) /Pharmacien Responsable of Guerbet.

The Board of Directors moreover decided to adhere to most of the provisions of the AFEP/MEDEF code of corporate governance.

The Board of Directors has established four special committees:

- The Strategy Committee and the Compensation Committee chaired by Mr. Jean-Jacques Bertrand;
- The Audit Committee and Research and Innovation Committee chaired by Mr. Jacques Biot.

The Board of Directors appointed Dr Michel Guerbet to serve as Honorary Chairman.

About Guerbet

Guerbet is the only pharmaceutical group fully dedicated to medical imaging worldwide. It has a comprehensive range of x-ray, MRI and nuclear medicine imaging products. These products assist medical professionals (radiologists, cardiologists, oncologists, etc.) in better diagnosing and treating their patients (cardiovascular, cancer, inflammatory and degenerative diseases).

To develop new products and assure its future growth, every year Guerbet devotes significant resources to research and development with 180 R&D employees and an amount equivalent to approximately 10% of sales. Programmes focusing on MRI technologies and nuclear medicine are key priorities of Guerbet Research.

Guerbet is solidly positioned in Europe with a market share of 25% and is expanding its presence in the United States and Japan.

Guerbet, listed on Eurolist Euronext Paris in compartment B had sales in 2009 of €335 million with a total workforce of 1,300 employees.

For additional information about Guerbet, please consult: www.guerbet.com.

Press contact:

Econeo: +33 (0) 1 47 61 89 68.